Journal Information
Vol. 86. Issue 1.
Pages 90-91 (January - March 2021)
Vol. 86. Issue 1.
Pages 90-91 (January - March 2021)
Clinical image in Gastroenterology
Open Access
Nivolumab-induced gastritis in a patient with metastatic melanoma
Gastritis inducida por nivolumab en un paciente con melanoma metastásico
D. Martínez-Acitores de la Mataa,
Corresponding author

Corresponding author at: Complejo Hospitalario de Navarra. Calle de Irunlarrea, 3, 31008, Pamplona, Navarra. Tel.: +34 629744259.
, V. Busto-Beaa, C. Cerezo-Aguirreb
a Departamento de Gastroenterología, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
b Departamento de Patología, Complejo Hospitalario de Navarra, Pamplona, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Figures (2)
Full Text

A 70-year-old man with metastatic melanoma (T3bN2M1) treated with nivolumab (62 cycles, 3 mg/kg every 14 days) for the last 2.5 years was admitted to the hospital with epigastric pain, hyporexia, and vomiting of one-month progression. Laboratory data and abdominal computed tomography showed no significant findings. Esophagogastroduodenoscopy was performed, revealing thick mucosal exudates, diffuse congestion, edema, erythema, and friability of the gastric mucosa (Fig. 1). Gastric biopsies showed an inflammatory cell infiltrate in the lamina propria, crypt abscesses, and glandular destruction (Fig. 2), suggestive of an adverse event related to nivolumab therapy. There was no evidence of Helicobacter pylori (H. pylori) infection. Nivolumab was discontinued and the patient received proton pump inhibitor (PPI) therapy. The patient was discharged 3 weeks after admission and remains asymptomatic 6 months after nivolumab suspension. Immune checkpoint inhibitors, such as nivolumab, are frequently associated with gastrointestinal adverse events. Diarrhea and enterocolitis are the more common presentations, and esophagitis and gastritis are rare. Nivolumab-induced gastritis can benefit from immunotherapy cessation, PPI use, and corticosteroid therapy. Testing for H. pylori infection should be carried out, as said bacterium can worsen the clinical course.

Figure 1.

Esophagogastroduodenoscopy showing thick mucosal exudates with diffuse mucosal congestion, edema, and erythema, as well as gastric atrophy.

Figure 2.

A) Gastric biopsy shows marked architectural distortion secondary to the presence of a dense inflammatory infiltrate within the lamina propria (H&E x100). B) The inflammatory infiltrate is mainly composed of neutrophils (black arrow) but eosinophils are also present (white arrow). Cryptitis (arrowheads) and crypt abscesses (asterisk) are prominent (H&E x200).

Ethical considerations

The patient provided his informed consent to receive the treatment and participate in the present research, which complies with the current regulations on bioethical research and was authorized by the institutional ethics committee.

The authors declare that the present article contains no personal information that could identify the patient.

Financial disclosure

No financial support was received in relation to this study/article.

Conflict of interest

The authors declare that there is no conflict of interest.

Please cite this article as: Martínez-Acitores de la Mata D, Busto-Bea V, Cerezo-Aguirre C. Gastritis inducida por nivolumab en un paciente con melanoma metastásico. Revista de Gastroenterología de México. 2021;86:90–91.

Copyright © 2020. Asociación Mexicana de Gastroenterología
Revista de Gastroenterología de México
Article options
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.